Table 4.
Overview and characteristics of studies discussing BMI and biochemical recurrence of prostate cancer in Asia
| Author, year [Ref] | Location | Patients | BMI (kg/m2) | HR (95 % CI) | HR per 5 kg/m2 increase of BMI (95 % CI) | Adjusted confoundersa |
|---|---|---|---|---|---|---|
| Bai 2015 | China | N = 211, 2006–2014, FUT = 24.5 months | Continuous | 1.145(1.029–1.273) | 1.97(1.15–3.34) | 1, 2, 7, 8 |
| Ohwaki 2015 [15] | Japan | N = 283, 2008–2012, FUT = 30 months | ≥25 vs. <25 | 0.83(0.40–1.72) | 0.83(0.40–1.72) | 1, 2, 7, 8 |
| Koo 2014 [10] | Korea | N = 880, 2005–2011, FUT = 58.2 months | >23 vs. ≤23 | 0.63(0.46–0.89) | 0.63(0.46–0.89) | 2, 5, 6, 7, 8, 14 |
| Hayashi 2014 [12] | Japan | N = 703, 2002–2009, FUT = 38.4 months | Continuous | 1.07(1.01–1.14) | 1.40(1.05–1.93) | 1, 2, 7, 8, 9, 10, 15 |
| Narita 2013 [9] | Japan | N = 1257, 2001–2009, FUT = 49 months | Continuous | 0.987(0.940–1.035) | 0.94(0.73–1.19) | 1, 2, 7, 8, 9, 10, 11 |
| Lee 2011 [13] | Korea | N = 512, 2003–2009, FUT = 37.8 months | Continuous | 1.373(0.720–2.326) | 4.88(0.19–68.08) | 1, 2, 3, 7, 8, 9, 10 |
| Komaru 2010 [14] | Japan | N = 173, 1997–2007, FUT = 35 months | ≥25 vs. <25 | 1.398(0.694–2.817) | 1.40(0.69–2.82) | None |
| Hisasue 2008 [8] | Japan | N = 126, 1998–2006, FUT = 17 months | ≥26.4 vs. <26.4 | 3.53(1.289–9.677) | 3.53(1.29–9.68) | 1, 2, 4, 7, 8, 12, 13 |
Ref reference, FUT follow-up time; other abbreviations as in Tables 1, 2, and 3
aAdjusted confounders: 1, age; 2, preoperative PSA; 3, prostate volume; 4, clinical stage; 5, lymphovascular invasion; 6, perineural invasion; 7, pathological Gleason score; 8, positive surgical margin; 9, extraprostatic extension; 10, seminal vesicle invasion; 11, lymph node involvement; 12, surgical period; 13, total testosterone; 14, pathological T stage; 15, adjuvant radiotherapy